← Back to Search

Dietary Supplement

Creatine Monohydrate for Alzheimer's Disease (CABA Trial)

N/A
Recruiting
Led By Matthew Taylor, PhD, RD
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed cognitive impairment due to Alzheimer's disease
Age 60 to 90
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 4 weeks, and 8 weeks
Awards & highlights

CABA Trial Summary

This trial will test whether creatine monohydrate can help treat Alzheimer's disease.

Who is the study for?
This trial is for English-speaking adults aged 60-90 with Alzheimer's, who have a BMI of at least 20.0kg/m2 and stable medication use for the past month. Participants need a study partner and can't be in other trials, require insulin, have had recent cancer treatments or cardiac events, weigh over 350 lbs., or suffer from kidney/liver issues.Check my eligibility
What is being tested?
Researchers are testing whether creatine monohydrate can improve energy production in brain cells and help manage Alzheimer's disease symptoms. The study involves taking creatine supplements to see if they benefit cognitive function.See study design
What are the potential side effects?
Creatine may cause side effects like stomach pain, nausea, muscle cramping, and diarrhea. It might also affect kidney function when taken in large doses over long periods.

CABA Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cognitive issues are due to Alzheimer's disease.
Select...
I am between 60 and 90 years old.

CABA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 4 weeks, and 8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 4 weeks, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adherence to Creatine Monohydrate Intervention
Change in Blood Creatine
Secondary outcome measures
Change in Brain Creatine Status
Change in Cognition
Muscle Tissue
+2 more

CABA Trial Design

1Treatment groups
Experimental Treatment
Group I: Creatine Monohydrate ArmExperimental Treatment1 Intervention
This study a single arm intervention. All participants will receive 20 grams of creatine monohydrate daily for the whole intervention (8 weeks).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Creatine Monohydrate
2009
Completed Phase 2
~170

Find a Location

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
459 Previous Clinical Trials
169,084 Total Patients Enrolled
Alzheimer's AssociationOTHER
89 Previous Clinical Trials
40,743 Total Patients Enrolled
Matthew Taylor, PhD, RDPrincipal InvestigatorUniversity of Kansas Medical Center

Media Library

Creatine Monohydrate (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT05383833 — N/A
Alzheimer's Disease Research Study Groups: Creatine Monohydrate Arm
Alzheimer's Disease Clinical Trial 2023: Creatine Monohydrate Highlights & Side Effects. Trial Name: NCT05383833 — N/A
Creatine Monohydrate (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05383833 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many subjects are enrolled in this research project?

"That is correct. The information available on clinicaltrials.gov suggests that the trial is still recruiting patients. 20 individuals are needed from 1 site, and the posting date was November 30th, 2020 with the most recent update being on November 1st, 2020."

Answered by AI

Are people of all ages being accepted for this trial, or are there age restrictions?

"As long as they are between 60 and 90 years old, patients of any age can participate in this clinical trial."

Answered by AI

Are patients currently being signed up for this research study?

"That is correct. The online clinicaltrials.gov registry currently lists this study as recruiting patients. 20 participants are needed for the trial which is set to take place at a single location. This particular research project was first posted on 11/30/2022 and received its most recent update on 11/1/2022."

Answered by AI

Who does this research project require for participation?

"20 individuals with Alzheimer's disease will be enrolled in this trial. The participants must meet the following requirements: They must have a diagnosis of cognitive impairment due to Alzheimer's disease, they must have a study partner who agrees to cooperate, they must speak English as their primary language, they must be between the ages 60 and 90, they must have been on stable medication for at least 30 days prior to enrolling in the study,, and their body mass index (BMI) must be greater than or equal to 20.0kg/m2."

Answered by AI

Why was this particular clinical trial designed and what are its goals?

"The primary goal of this 8-week clinical trial is to study the effect of the experimental medication on blood creatine levels. Additionally, changes in peripheral mitochondrial respiration (oxygen consumption), muscle strength, and cognition will be measured as secondary outcomes."

Answered by AI
~10 spots leftby Jun 2025